Jun 2026 (Q2 FY26) — Aug 5, 2026
LivaNova Q2 FY26 — Record Revenue & EPS Driven by CP and Epilepsy Strength
Read the full callLivaNova (LIVN) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
LivaNova earnings: last reported Wed, 5 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 391 | +10.8% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 12.7 | −2.7 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 109 | +299.7% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
$78.14 +0.72% · +$0.56
Performance +45.4% 1Y
1Y: $53.73 on 17 Oct 2025 → $78.14. High $85.33 (4 Aug 2026), low $49.57 (6 Nov 2025).
- Previous close
- $77.58
- 52-week range
- $49.57 – $85.33
- One year
- +44.44%
Overview
- Symbol
- LIVN
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Mar 2026 (Q1 FY26) — May 6, 2026
LivaNova Q1 FY26 — Strong Revenue Growth Across Segments Driven by Essenz and Epilepsy Reimbursement
Read the full callDec 2025 (Q4 FY25) — Feb 25, 2026
LivaNova Q4 FY25 — Double-Digit Growth and Strategic Advancements
Read the full callEvery analysed call
LivaNova earnings calls (LIVN)
Financials
What the filings say
Net profit, year on year: +300% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 318 | 322 | 317 | 353 | 358 | 361 | 362 | 391 |
| Operating profit | 36 | 37 | 49 | 54 | 54 | 43 | 41 | 49 |
| Operating margin | 11.2% | 11.5% | 15.3% | 15.4% | 15.1% | 11.8% | 11.4% | 12.7% |
| Other income | 25 | 35 | 11 | -4 | -7 | -2 | -6 | -24 |
| Interest | 16 | 16 | 15 | 15 | 11 | 11 | 8 | 7 |
| Profit before tax | 44 | 56 | -316 | 33 | 34 | 28 | 27 | 18 |
| Tax rate | 25.9% | 1.0% | −3.7% | 18.5% | 21.0% | −11.9% | 15.8% | −488.1% |
| Net profit | 33 | 56 | -327 | 27 | 27 | 31 | 22 | 109 |
| EPS ($ per share) | 0.61 | — | -6.01 | 0.50 | 0.49 | — | 0.41 | 1.98 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 76 | 76 | 76 | 82 | 82 | 83 | 83 | 85 |
| Reserves | -252 | -407 | -762 | -898 | -984 | -966 | -903 | -1,146 |
| Total liabilities | 1,046 | 1,028 | 1,291 | 906 | 1,087 | 1,152 | 1,186 | 1,406 |
| Fixed assets | 191 | 181 | 164 | 150 | 147 | 154 | 170 | 243 |
| Total assets | 2,550 | 2,412 | 2,400 | 2,201 | 2,295 | 2,430 | 2,506 | 2,606 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 120 | -91 | -79 | 103 | 70 | 75 | 183 | 254 |
| Cash from investing | -121 | -41 | -42 | 37 | -38 | -40 | -48 | -73 |
| Cash from financing | -42 | 147 | 311 | -181 | 280 | 21 | 19 | -286 |
| Net cash flow | -46 | 14 | 192 | -45 | 308 | 62 | 146 | -88 |
| Capital expenditure | -37 | -25 | -35 | -25 | -27 | -35 | -47 | -81 |
| Free cash flow | 83 | -116 | -114 | 77 | 43 | 40 | 136 | 173 |
LIVN revenue by segment
| Segment | Q3 FY2024 | Q4 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | YoY growth latest quarter |
|---|---|---|---|---|---|---|---|---|---|
| Cardiopulmonary | 54% | 56% | 56% | 57% | 57% | 57% | 58% | 57% | +11.2% |
| Neuromodulation | 44% | 43% | 44% | 43% | 42% | 42% | 42% | 43% | +10.1% |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
Revenue by region
Q2 FY2026 · share of revenue
- US 51% ↓ 5 pt
- Locations Excluding The United States and Europe 28% ↑ 1 pt
- Europe 21% ↑ 4 pt
As LIVN cuts its regions in its filings; they can nest, so they need not add to 100%.
Insider filings
51 filings between Nov 18, 2025 and Sep 10, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$1.05M
7 sales by 3 insiders
Compensation
not trading decisions- 21
- Option exercise — converted options into shares
- 22
- Tax withheld — shares kept back by the company to cover tax
Also filed: 1 disposition to issuer.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Bianchi Francesco | — | $637.1K | Sep 10, 2026 |
| Tezel Ahmet | — | $207.9K | Aug 11, 2026 |
| Story Brooke | — | $200.8K | Sep 4, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 10, 2026 | Bianchi Francesco Director | Sale | 3,500 | $273.0K |
| Sep 4, 2026 | Story Brooke Director | Sale | 2,300 | $187.3K |
| Aug 31, 2026 | Bianchi Francesco Director | Sale | 1,650 | $131.5K |
| Aug 11, 2026 | Tezel Ahmet Chief Innovation Officer | Sale | 2,675 | $207.9K |
| Aug 11, 2026 | Tezel Ahmet Chief Innovation Officer | Option exercise | 12,692 | $668.6K |
| Aug 11, 2026 | Tezel Ahmet Chief Innovation Officer | Disposition to issuer | 8,589 | $668.7K |
| Aug 11, 2026 | Tezel Ahmet Chief Innovation Officer | Tax withheld | 1,428 | $111.2K |
| Jun 15, 2026 | Zurbay Donald Director | Tax withheld | 308 | $24.5K |
| Jun 15, 2026 | Story Brooke Director | Option exercise | 4,042 | $0 |
| Jun 15, 2026 | Story Brooke Director | Tax withheld | 486 | $38.7K |
| Jun 15, 2026 | Enxing Seng Stacy Director | Option exercise | 4,042 | $0 |
| Jun 15, 2026 | Enxing Seng Stacy Director | Tax withheld | 486 | $38.7K |
| Jun 15, 2026 | KOZY WILLIAM A Director | Option exercise | 5,681 | $0 |
| Jun 15, 2026 | KOZY WILLIAM A Director | Tax withheld | 682 | $54.4K |
| Jun 15, 2026 | Tezel Ahmet Chief Innovation Officer | Option exercise | 2,965 | $0 |
| Jun 15, 2026 | Tezel Ahmet Chief Innovation Officer | Tax withheld | 1,032 | $82.3K |
| Jun 15, 2026 | Barry James Christopher Director | Option exercise | 4,042 | $0 |
| Jun 15, 2026 | Barry James Christopher Director | Tax withheld | 486 | $38.7K |
| Jun 15, 2026 | PODLOGAR SUSAN M Director | Option exercise | 4,042 | $0 |
| Jun 15, 2026 | PODLOGAR SUSAN M Director | Tax withheld | 486 | $38.7K |
| Jun 15, 2026 | Bianchi Francesco Director | Option exercise | 4,042 | $0 |
| Jun 15, 2026 | Bianchi Francesco Director | Tax withheld | 486 | $38.7K |
| Jun 15, 2026 | Bianchi Francesco Director | Sale | 1,200 | $96.2K |
| Jun 15, 2026 | SCHERMERHORN TODD C Director | Option exercise | 4,042 | $0 |
| Jun 15, 2026 | SCHERMERHORN TODD C Director | Tax withheld | 486 | $38.7K |
| Jun 15, 2026 | Zurbay Donald Director | Option exercise | 2,560 | $0 |
| Jun 15, 2026 | WILVER PETER M Director | Option exercise | 4,042 | $0 |
| Jun 15, 2026 | WILVER PETER M Director | Tax withheld | 486 | $38.7K |
| May 26, 2026 | Bianchi Francesco Director | Sale | 1,800 | $136.3K |
| Mar 30, 2026 | Bolton Stephanie President, Global Epilepsy | Tax withheld | 8,377 | $513.3K |
| Mar 30, 2026 | Makatsaria Vladimir Chief Executive Officer | Option exercise | 21,042 | $0 |
| Mar 30, 2026 | Makatsaria Vladimir Chief Executive Officer | Tax withheld | 11,159 | $683.7K |
| Mar 30, 2026 | Shvartsburg Alex Chief Financial Officer | Option exercise | 30,835 | $0 |
| Mar 30, 2026 | Shvartsburg Alex Chief Financial Officer | Tax withheld | 12,868 | $788.4K |
| Mar 30, 2026 | Poletti Franco President, Cardiopulmonary | Option exercise | 3,184 | $0 |
| Mar 30, 2026 | Poletti Franco President, Cardiopulmonary | Tax withheld | 1,370 | $83.9K |
| Mar 30, 2026 | Tezel Ahmet Chief Innovation Officer | Option exercise | 3,408 | $0 |
| Mar 30, 2026 | Tezel Ahmet Chief Innovation Officer | Tax withheld | 1,186 | $72.7K |
| Mar 30, 2026 | Bolton Stephanie President, Global Epilepsy | Option exercise | 17,815 | $0 |
| Mar 30, 2026 | Kozmina Natalia Chief Human Resources Officer | Tax withheld | 1,374 | $84.2K |
| Mar 30, 2026 | Kozmina Natalia Chief Human Resources Officer | Option exercise | 6,389 | $0 |
| Mar 11, 2026 | Poletti Franco President, Cardiopulmonary | Option exercise | 2,140 | $123.3K |
| Mar 11, 2026 | Poletti Franco President, Cardiopulmonary | Tax withheld | 1,980 | $123.3K |
| Mar 11, 2026 | Poletti Franco President, Cardiopulmonary | Tax withheld | 69 | $4.3K |
| Dec 15, 2025 | Hutchinson Michael Damon SVP, CLO and Company Secretary | Option exercise | 2,254 | $0 |
| Dec 15, 2025 | Hutchinson Michael Damon SVP, CLO and Company Secretary | Tax withheld | 1,122 | $70.8K |
| Dec 15, 2025 | Poletti Franco President, Cardiopulmonary | Tax withheld | 416 | $26.2K |
| Dec 15, 2025 | Poletti Franco President, Cardiopulmonary | Option exercise | 967 | $0 |
| Dec 15, 2025 | PODLOGAR SUSAN M Director | Option exercise | 2,355 | $0 |
| Dec 15, 2025 | PODLOGAR SUSAN M Director | Tax withheld | 269 | $17.0K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for LivaNova PLC
Free account. Everything above stays public.
Write why you follow LivaNova PLC and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading